

## Financial Tear Sheet

### Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

### Stock Information

| XBIT (Common Stock)              |                    |
|----------------------------------|--------------------|
| Exchange                         | NASDAQ (US Dollar) |
| Price                            | \$5.93             |
| Change (%)                       | ▲ 0.24 (4.22%)     |
| Volume                           | 90,037             |
| 52 Week Low                      | \$2.13             |
| Market Cap                       | \$203,814,503      |
| Rolling EPS                      | -0.65              |
| PE Ratio                         | 0                  |
| Shares Outstanding               | 35,819,772         |
| Data as of 01/17/19 4:00 p.m. ET |                    |



Data provided by Nasdaq. Minimum 15 minutes delayed.

### Recent News

| Date     | Title  |
|----------|--|
| 12/13/18 | XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study      |
| 12/12/18 | XBiotech's Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease |
| 12/03/18 | XBiotech Announces Successful Completion of GMP Audit  |

### Upcoming Events

There are currently no events scheduled.

### SEC Filings

### Primary IR Contact

| Filing Date | Form |
|-------------|------|
| 12/28/18    | 4    |
| 12/20/18    | 4    |
| 11/13/18    | 4    |
| 10/31/18    | 10-Q |

James S. Whitehurst  
 XBiotech  
**Phone:** +1 512.386.2993  
**Email:** swhitehurst@xbiotech.com

## Management

John Simard Founder, President, Chief Executive Officer & Chairman

Norma I. Gonzalez Vice President of Quality

Queena Han, C.P.A., C.G.A. Vice President of Finance and Human Resources and Secretary

Sushma Shivaswamy, Ph.D. Chief Scientific Officer

## Board of Directors

John Simard Founder, President, Chief Executive Officer & Chairman

Thorpe McKenzie Director

Jan-Paul Waldin Director

Donald H. MacAdam Director